SCHEMBL23526499

SCHEMBL23526499

Cc1c(Cl)cccc1[C@@H](C)N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.67
PNMT P11086 2/20 0.67
CYP1A2 P05177 1/20 0.67
CYP2D6 P10635 1/20 0.67
NFKB1 P19838 1/20 0.67
ALDH1A1 P00352 3/20 0.64
LMNA P02545 3/20 0.64
GLA P06280 1/20 0.64
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.45
CFD P00746 1/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
TSHR P16473 1/20 0.37
PIK3CA P42336 1/20 0.37
POLB P06746 1/20 0.37
ADRB2 P07550 1/20 0.37
NISCH Q9Y2I1 1/20 0.36
CXCL8 P10145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1467055 1.00 CYP3A4 (0.67) CYP3A4PNMTCYP1A2CYP2D6NFKB1
SCHEMBL23563480 0.84 ALDH1A1 (0.52) CYP3A4PNMTCYP1A2CYP2D6NFKB1
SCHEMBL24569288 0.84 ALDH1A1 (0.50) CYP3A4PNMTCYP1A2CYP2D6NFKB1
SCHEMBL2737309 0.82 CYP1A2 (0.48) CYP3A4PNMTCYP1A2CYP2D6NFKB1
SCHEMBL8207165 0.80 PNMT (1.00) CYP3A4PNMTCYP1A2CYP2D6NFKB1
SCHEMBL158333 0.80 PNMT (1.00) CYP3A4PNMTCYP1A2CYP2D6NFKB1
SCHEMBL8207792 0.80 PNMT (1.00) CYP3A4PNMTCYP1A2CYP2D6NFKB1
SCHEMBL9985739 0.79 CYP3A4 (0.68) CYP3A4PNMTCYP1A2CYP2D6NFKB1
SCHEMBL29668896 0.79 CYP3A4 (0.68) CYP3A4PNMTCYP1A2CYP2D6NFKB1
SCHEMBL4706452 0.79 CYP3A4 (0.68) CYP3A4PNMTCYP1A2CYP2D6NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382290-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-12-18 US disclosed
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
EP-4543450-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-30 EP disclosed
CN-119546304-A Salts of SOS1 inhibitors 米拉蒂治疗公司 2025-02-28 CN disclosed
US-20250059182-A1 SOS1 INHIBITORS MIRATI THERAPEUTICS, INC 2025-02-20 US disclosed
CN-119462626-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2025-02-18 CN disclosed
CN-115135315-B SOS1 inhibitors 米拉蒂治疗股份有限公司 2024-11-26 CN disclosed
WO-2023250165-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-28 WO disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-20230137886-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2023-05-04 US disclosed
US-20230137886-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2023-05-04 US disclosed
WO-2022271679-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2022-12-29 WO disclosed
CN-115135315-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2022-09-30 CN disclosed
US-20210188857-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2021-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382290-A1 SALTS OF SOS1 INHIBITORS SOS1, SOS2, SOST CYP3A4 4750/4885PNMT 4674/4885CYP1A2 4661/4885
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 CYP3A4 4860/4885PNMT 4056/4885CYP1A2 4781/4885
US-20250059182-A1 SOS1 INHIBITORS SOS1, SOS2, SOST CYP3A4 4856/4885PNMT 4500/4885CYP1A2 4753/4885
US-20230137886-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 CYP3A4 4860/4885PNMT 4056/4885CYP1A2 4781/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 CYP3A4 4860/4885PNMT 4056/4885CYP1A2 4781/4885
US-20210188857-A1 SOS1 INHIBITORS SOS1, SOS2, SOST CYP3A4 4856/4885PNMT 4500/4885CYP1A2 4753/4885
US-11702418-B2 SOS1 inhibitors SOS1, SOS2, SOST CYP3A4 4856/4885PNMT 4500/4885CYP1A2 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.